Ignite Creation Date:
2024-05-06 @ 2:32 AM
Last Modification Date:
2024-10-26 @ 11:19 AM
Study NCT ID:
NCT02060409
Status:
COMPLETED
Last Update Posted:
2014-02-12
First Post:
2014-02-10
Brief Title:
Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Study Overview
Official Title:
Prognostic Molecular Markers Determined by Using Gene Expression Profiling in Patients With Myelodysplastic Syndrome
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In the era of hypomethylating agent in MDS treatment the investigators aimed to investigate the prognostic impact of mutations in spliceosome machinery genes SRSF2 U2AF1 and ZRSR2 on the outcomes of 1st line decitabine treatment in MDS
Detailed Description:
A number of studies have tried to investigate clinical impact of mutations in spliceosomal machinery genes in MDS but they failed to demonstrate a consistent prognostic relevance Moreover the clinical impact of these mutations on the outcomes of hypomethylating agent treatment in MDS has never been explored yet The investigators investigated the prognostic impact of mutations in spliceosome machinery genes SRSF2 U2AF1 and ZRSR2 on the outcomes of 1st line decitabine treatment in MDS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None